Evolution of androgen deprivation therapy

Ganesh V. Raj, Luke A. Selth, Tanya K. Day, Wayne D. Tilley

Research output: Contribution to journalReview articlepeer-review


The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/or blocking the androgen receptor, collectively termed androgen deprivation therapy. This review will discuss the evolution of androgen deprivation therapy since it was instigated more than 70 years ago, and outline the key mechanisms underlying its inevitable failure. We will also briefly introduce potential new androgen signalling-targeted therapies in clinical development.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalCancer Forum
Issue number3
Publication statusPublished - Nov 2015
Externally publishedYes


Dive into the research topics of 'Evolution of androgen deprivation therapy'. Together they form a unique fingerprint.

Cite this